Item 5.02Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of President and Chief Executive Officer
On February 24, 2023, Evripides Drakos resigned as the President and Chief
Executive Officer of the Company, in furtherance of the Company's planned
restructuring as part of its fundraising efforts, and to facilitate the
appointment of Dr. Michael R. Hawthorne as the President and Chief Executive
Officer of the Company.
Appointment of President and Chief Executive Officer
On February 24, 2023, the Company elected Michael R. Hawthorne, the current
Deputy Chief Executive Officer, to serve as the President and Chief Executive
Officer of the Company. Mr. Hawthorne does not have a material interest in any
transaction that is required to be disclosed under Item 404(a) of Regulation
S-K, and there is no family relationship between Mr. Hawthorne and any of the
Company's other directors or executive officers.
Dr. Hawthorne was appointed our deputy chief executive officer on February 11,
2022. Dr. Hawthorne has served as the executive chairman of Domainex Ltd
(Cambridge, UK), a global drug discovery contract research organization, since
August 2021 and as an advisor to Closed Loop Medicine Ltd (London, UK) since
2017. Dr. Hawthorne was awarded a Fellowship of The Royal Society of Biology in
2020 in recognition of his contribution to global biosciences. Dr. Hawthorne is
an investor and has served as a director of BG Capital (USA) from 2016 to
present.
Departure of Director
On February 26, 2023, Moshe Morgenstern tendered his resignation as a member of
the Board of Directors of the Company.
--------------------------------------------------------------------------------
Page 2
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
BAKHU HOLDINGS, CORP. 
